Assessment of Sulfonylurea Adherence and Metabolic Control

Mason, Barbara J.; Matsuyama, Joy R.; Jue, Sandra G.

doi:10.1177/014572179502100109

Cited by 61 publications

(48 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two studies showed that adherence to oral medications in patients with type 2 diabetes was 53 and 67% when measured by electronic monitoring. 11,12 The DAWN study showed patient-reported adherence rates for medication in type 1 and type 2 diabetic patients of 83 and 78%, respectively. 5 In another study overall 45.1% of patients of type 2 DM were adherent with their study drug over the 1-year follow-up period.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Adherence to Therapy In Patients of Type 2 Diabetes Mellitus

Sontakke¹,

Jadhav²,

Pimpalkhute³

et al. 2015

J YOUNG PHARM

View full text Add to dashboard Cite

Objective: To evaluate adherence to therapy and study factors associated with non-adherence in patients of type 2 diabetes mellitus (DM). Methods: A prospective, cross-sectional, questionnaire based study was conducted in a tertiary care teaching hospital. 150 patients suffering from type 2 DM since six months or more were interviewed using self-designed, semistructured questionnaire to get information about adherence to medication, diet/exercise schedule and self-monitoring of blood glucose. Morisky medication adherence questionnaire was used to calculate overall adherence. Results: Average number of medicines taken by each patient daily was 4.75 ± 1.73 (mean + SD). 70% patients reported non-adherence to medication schedule. Not buying all medicines (58.66%), not taking prescribed dose of medicines (34%), taking additional non-prescribed medicines (30%) and not taking medicines for required duration (25.33%) were common types of nonadherence. Unawareness about need of each medicine (55.66%), forgetfulness (50.66%) and high cost (43.33%) were the common causes of non-adherence. In Morisky medication adherence questionnaire high, medium and low adherence was reported by 0%, 26% and 74% of patients, respectively. Moderately positive correlation was observed between poor adherence and number of concurrent illnesses, number of medicines taken and female gender. Regular monitoring of blood glucose and diet schedule was followed by 46% and 68% patients respectively. Conclusion: Since, not buying all medicines, which was mostly due to high cost was the commonest type of non-adherence, measures to provide free medicines to non-affording patients need to be implemented. Majority of patients were not aware about need of taking each medicine, hence, creating awareness about the same is essential for improving adherence to therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of Adherence to Therapy In Patients of Type 2 Diabetes Mellitus

Sontakke¹,

Jadhav²,

Pimpalkhute³

et al. 2015

J YOUNG PHARM

View full text Add to dashboard Cite

show abstract

“…It may also be argued that actual ingestion of the medication was not measured, because the electronic device recorded only when the bottle was opened. However, regularity of bottle opening, measured with the same device, has been correlated with efficacy of treatment of hyperlipidemia (42) and diabetes (43). The study had a number of strengths.…”

Section: Discussionmentioning

confidence: 99%

Treatment Completion and Costs of a Randomized Trial of Rifampin for 4 Months versus Isoniazid for 9 Months

Menzies

Dion

Rabinovitch

et al. 2004

Am J Respir Crit Care Med

153

119

View full text Add to dashboard Cite

There is little published information regarding treatment completion, safety, and efficacy of rifampin administered daily for 4 months-a recommended alternative to 9 months of isoniazid for therapy of latent tuberculosis infection. In an open-label randomized trial at a university-affiliated respiratory hospital, consenting patients whose treating physician had recommended therapy for latent tuberculosis infection were randomized to daily self-administered rifampin for 4 months or daily self-administered isoniazid for 9 months. Of 58 patients randomized to rifampin, 53 (91%) took 80% of doses, and 50 (86%) took more than 90% of doses within 20 weeks compared with 44 (76%) and 36 (62%) who took 80 and 90%, respectively, of doses of isoniazid within 43 weeks (relative risks: 80% of doses, 1.2 [95% confidence interval: 1.02, 1.4]; 90% of doses, 1.4 [1.1, 1.7]). Adverse events resulted in permanent discontinuation of therapy for two (3%) patients taking rifampin, and for eight (14%) patients taking isoniazid. Three patients developed druginduced hepatitis-all were taking isoniazid. Total costs of therapy were significantly higher for isoniazid. In conclusion, completion of therapy was significantly better with 4 months of rifampin and major side effects were somewhat lower. Further studies are needed to assess the safety and efficacy of the 4-month rifampin regimen. Keywords: latent tuberculosis infection; treatment of latent tuberculosis infection; tuberculosis preventionA major activity of many tuberculosis (TB) control programs in industrialized countries is the identification of persons with latent TB infection (LTBI), who have increased risk of development of active TB. Treatment of such individuals can provide individual (1-6) and public health (4-8) benefits. The current recommended standard therapy is 9 months of isoniazid (9INH). This has an efficacy of more than 90% (9) if taken properly. However, because of the long duration, only 64-67% of patients (10, 11) or fewer (12) complete therapy under routine program conditions. Another limitation of INH is the occurrence of druginduced hepatitis. Although rare, this can be fatal (13-17). The incidence of this complication appears to have diminished over the past three decades (10,18,19), but nevertheless this remains an important disadvantage of INH therapy. As well, the long duration, and need for close monitoring because of the possibility of serious adverse events, make this regimen relatively costly.

show abstract

“…At present, measurement of adherence in studies of osteoporosis relies mostly on pill counts and selfreporting [43]. Pill counts and self-reporting overestimate true compliance [44][45][46][47][48][49]. In addition, they provide no information on the patient's behaviour surrounding drug intake.…”

Section: How To Investigate Adherencementioning

confidence: 99%